Business
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of “Maravai LifeSciencesReleases 2024 Sustainability Report”. The corrected title is “Maravai LifeSciences Releases 2024 Sustainability Report”. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company’s Sustainability webpage (investors.maravai.com/sustainability). The new report highlights progress during calendar year 2024 across Maravai’s four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company’s commitment to sustainable value creation. “By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,” said Trey Martin, Chief Executive Officer. “Our 2024 achievements position Maravai to remain our customers’ first choice as they advance their programs in next-generation therapeutics and diagnostics.” Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP qualityCompleted state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfoldEstablished RNA Innovation Center in collaboration with Johns Hopkins UniversityAdded to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 commentsExpanded WE (We are Empowered) Employee Resource Group to facili...